TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18435392
Drug: Two Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two Arm Group (one vaccine in each arm)
Study: 12511765
Drug: Antidepressive medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressive medication (exact dosage and duration not specified)
Study: 10682151
Drug: Zidovudine/lamivudine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine/lamivudine combination therapy
Study: 7027040
Drug: Dialysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis treatment time (long or short)
Study: 28495391
Drug: Embodied Conversational
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embodied Conversational Agent (ECA)
Study: 25716637
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 (50,000 IU weekly)
Study: 24016557
Drug: Type A
Normalized name: HLA type A IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type A treatment
Study: 24016557
Drug: Type B
Normalized name: HLA type B IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type B treatment
Study: 24016557
Drug: Type C
Normalized name: HLA type C IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type C treatment
Study: 24016557
Drug: Type D
Normalized name: HLA II type DQ IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type D treatment
Study: 24016557
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Glucocorticoid)
Study: 18087552
Drug: Verapamil (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (480 mg/d)
Study: 18087552
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 mg/d)
Study: 15476904
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 20 mg once daily for 12 months
Study: 9272793
Drug: Ketamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.15 mg/kg
Study: 9916610
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate ophthalmic gel-forming solution 0.5% QD
Study: 1606348
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg intravenous ciprofloxacin
Study: 27935735
Drug: Lisdexamfetamine (LDX)
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine (LDX) 70 mg/day for 5 weeks
Study: 21952094
Drug: IFNβ‐1b 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNβ‐1b 250 µg
Study: 21952094
Drug: IFNβ‐1b 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNβ‐1b 500 µg
Study: 21952094
Drug: IFNβ‐1b 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNβ‐1b 250 µg and 500 µg
Study: 21952094
Drug: Control (Glatiramer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Glatiramer acetate 20 mg)
Study: 19254906
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (400 microg/day)
Study: 25672894
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide and Placebo
Study: 18091071
Drug: Bromocriptine (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (dopamine agonist)
Study: 15302228
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg beta‐methyl‐6‐chloromelatonin
Study: 15302228
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of beta‐methyl‐6‐chloromelatonin
Study: 10958716
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg sildenafil
Study: 10223498
Drug: sildenafil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: sildenafil (all doses)
Study: 7851353
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release metoclopramide (Gastromax 30 mg)
Study: 2520372
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid treatment under occlusive dressings for 72 hours
Study: 17894041
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose thiothixene (40 mg.)
Study: 17894041
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose thiothixene (10 mg.)
Study: 26069137
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg (Group A)
Study: 26069137
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg (Group B)
Study: 16857887
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of micronized progesterone vaginally (progesterone group)
Study: 16857887
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of micronized progesterone and 4 mg of E2 valerate orally (progesterone/E2 group)
Study: 9283776
Drug: Extended insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended insulin regimen (5 U/h continued until resolution of hyperketonemia)
Study: 9283776
Drug: Extended insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended insulin regimen
Study: 9283776
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin regimen (5 U/h until near-normoglycemia, then reduced rate)
Study: 3051043
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (1 mg initial dose, followed by 1 mg or 2 mg 6 hours later if needed)
Study: 3051043
Drug: Intravenous perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous perfusion of synthetic oxytocin (starting at 1 mU/min, increased every 20 minutes)
Study: 24443001
Drug: 3×1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3×1000 mg rituximab
Study: 22921855
Drug: Terlipressin (TP)
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (TP) administered as a continuous intravenous dose of 1.3 μg/kg/h
Study: 22921855
Drug: Dopamine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine administered in doses up to 20 μg/kg/min
Study: 21399391
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg CoQ10 daily
Study: 19615314
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine plus American ginseng and Salviae miltiorrhizae preparations
Study: 12883913
Drug: Heparin surface-modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin surface-modified polymethylmethacrylate IOL (Pharmacia & Upjohn 809C)
Study: 9068769
Drug: Amisulpride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (100 mg/day)
Study: 20935692
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac (n = 9)
Study: 20935692
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac (n = 11)
Study: 20935692
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac (n = 8)
Study: 20935692
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac (n = 9)
Study: 17785764
Drug: Panitumumab 6
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 6 mg/kg every 2 weeks
Study: 20395618
Drug: donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil 5 mg/d
Study: 21612646
Drug: donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil 10 mg/d
Study: 10994000
Drug: Acetyl-l-carnitine (ALCAR)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-l-carnitine (ALCAR) 1 g tid
Study: 6303209
Drug: Cefmenoxime (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmenoxime (1.0 g)
Study: 6303209
Drug: Procaine penicillin
Normalized name: procaine penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine penicillin G (4.8 X 10(6) U) + probenecid (1.0 g orally)
Study: 30235387
Drug: Sarecycline 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarecycline 1.5 mg/kg/day
Study: 20008620
Drug: Dasatinib 50
Normalized name: dasatinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 50 mg twice daily
Study: 21455450
Drug: Agnikarma (cauterization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agnikarma (cauterization treatment)
Study: 7880187
Drug: Prednisone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (15 mg/day for 1 month, tapered thereafter)
Study: 2120362
Drug: Conventional mandibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional mandibular block injection technique
Study: 2120362
Drug: Closed-mouth mandibular
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-mouth mandibular block injection technique
Study: 23375406
Drug: Granisetron (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (1 mg twice daily)
Study: 21991733
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 microg/kg in 20 mL saline
Study: 21991733
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution 20 mL
Study: 15388819
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (NPD) (1.20+/‐0.06 g/kg/day)
Study: 15388819
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LPD) (0.66+/‐0.04 g/kg/day)
Study: 11352441
Drug: ranitidine 150mg
Normalized name: GoodSense Ranitidine 150mg Tablet
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150mg twice daily during a 3‐day pretreatment phase and 1 tablet of ranitidine with a single 400mg dose of moxifloxacin
Study: 9398108
Drug: Carteolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol (15 mg/day)
Study: 3297719
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with Vincristine, Cyclophosphamide, and Prednisone after regional radiotherapy in stage I
Study: 3297719
Drug: 8 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 courses of chemotherapy with Adriamycin, VM26, Cyclophosphamide, and Prednisone in stage III and IV
Study: 26729347
Drug: Progressive-resisted exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive-resisted exercise (PRE) intervention conducted twice weekly for 12 weeks
Study: 22366878
Drug: Usual daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual daily activities (Control group)
Study: 25472808
Drug: Transversus abdominis
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus abdominis plane block with ropivacaine 0.375% plus postoperative patient-controlled intravenous analgesia with morphine (TAP group, n = 50)
Study: 25472808
Drug: Perioperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative intravenous lidocaine plus postoperative patient-controlled intravenous analgesia with morphine (LIDO group, n = 50)
Study: 25472808
Drug: Postoperative patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative patient-controlled intravenous analgesia with morphine (control group, n = 25)
Study: 20467151
Drug: Pitavastatin or
Normalized name: pitavastatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin or Atorvastatin
Study: 18936764
Drug: DAG oil
Normalized name: Daglutril
DrugBank: Daglutril (DB05796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAG oil (10 g day(-1))
Study: 18936764
Drug: TAG oil
Normalized name: ProVent SKIN TAG OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAG oil (10 g day(-1))
Study: 8723457
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg i.v. every 8 h
Study: 8723457
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg i.v. every 12 h
Study: 30226339
Drug: EVE group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVE group: 5 mg of 0.5% isobaric bupivacaine plus 15 Âµg of fentanyl injection followed by 10 mL of sterile saline injection.
Study: 30226339
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: 10 mg of 0.5% isobaric bupivacaine plus 15 Âµg of fentanyl injection.
Study: 20068567
Drug: weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: weekly docetaxel with cisplatin and 5-fluorouracil (wTCF)
Study: 20068567
Drug: weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: weekly docetaxel with capecitabine (wTX)
Study: 18608841
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of model demonstrations and practice (with and without knowledge of performance)
Study: 18608841
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of model demonstrations and knowledge of performance practice
Study: 16123681
Drug: stavudine or
Normalized name: stavudine Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: stavudine or nucleoside reverse transcriptase inhibitor regimens not containing didanosine
Study: 6761122
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg alinidine
Study: 6761122
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg alinidine
Study: 6761122
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg alinidine
Study: 29417135
Drug: Guselkumab, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab, 200 mg, by subcutaneous injection at weeks 0 and 4
Study: 27051309
Drug: Low-dose SFC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SFC (100 µg, two puffs daily)
Study: 27051309
Drug: High-dose fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fluticasone propionate (FP) alone (500 µg, daily)
Study: 25280804
Drug: Outpatient interdisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient interdisciplinary rehabilitation programme consisting of 6 weeks of intensive physiotherapy and individual occupational therapy as needed.
Study: 9678811
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg b.d. with clarithromycin (500 mg) and amoxycillin (1000 mg) b.d. for 14 days
Study: 9678811
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg b.d. with clarithromycin (500 mg) and amoxycillin (1000 mg) b.d. for 14 days
Study: 2454343
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (etmozin, quinidine, mexytil, allapinin, cordarone) used alone
Study: 2454343
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of antiarrhythmic drugs
Study: 31952554
Drug: Short-course therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course therapy (SCT) - 5-day intravenous antimicrobial therapy if clinical improvement is observed
Study: 31952554
Drug: Conventional long-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional long-course therapy (LCT) - at least 7 days of intravenous antibiotics
Study: 22147778
Drug: Helium-oxygen therapy
Normalized name: helium / oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helium-oxygen therapy
Study: 19567452
Drug: Acenocumarine 1
Normalized name: Acenocoumarin
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acenocumarine 1 mg/day for 3 days before and 8 days after CVC insertion
Study: 19567452
Drug: Dalteparin 5000
Normalized name: dalteparin 5000 intl units/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 5000 IU 2 h before and daily for 8 days after CVC insertion
Study: 19567452
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant treatment (NT)
Study: 10512128
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion (CI) cisplatin 5 mg/m2/day plus etoposide 18 mg/m2/day for 5 days per week over 5 weeks with concurrent single daily fraction thoracic radiotherapy to 4500 cGy
Study: 2202264
Drug: TUR +
Normalized name: Trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TUR + BCG (75 mg)
Study: 2202264
Drug: BCG (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (75 mg) for therapy of carcinoma in situ
Study: 26809984
Drug: Pemetrexed plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G)
Study: 17929018
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (L-AmB)
Study: 17470822
Drug: Vitamin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin therapy (2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12)
Study: 12472998
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B 3D Excel power toothbrush (BPT)
Study: 9797188
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg L-NMMA
Study: 11004017
Drug: L-arginine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (30 g over 30 min)
Study: 8634659
Drug: beta‐carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐carotene (20 mg)
Study: 8634659
Drug: DL-alpha-tocopheryl acetate
Normalized name: DL-alpha-tocopheryl acetate
DrugBank: DL-alpha tocopheryl acetate (DB14477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-alpha-tocopheryl acetate (55 mg)
Study: 9161744
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg.kg‐1)
Study: 378005
Drug: Intravenous cephalothin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cephalothin
Study: 22298434
Drug: Pre-treatment patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment patient variables including personality disorder pathology
Study: 17087839
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 2 microg kg(‐1)
Study: 15041600
Drug: Dexamethasone 12
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 12 mg IV
Study: 15041600
Drug: Droperidol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.1 mg/mL with morphine in PCA
Study: 11133606
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg IV
Study: 15041600
Drug: Dexamethasone 2
Normalized name: dexamethasone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 2 mg IV
Study: 8990448
Drug: Oral HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HRT (estradiol 2.0 mg/d + norethisterone acetate 1.0 mg/d)
Study: 8990448
Drug: Transdermal HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal HRT (estradiol 50 micrograms/d + medroxyprogesterone acetate 10 mg/d)
Study: 8484508
Drug: Ketorolac, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac, 60 mg
Study: 3437794
Drug: 20 X
Normalized name: betibeglogene autotemcel 2 x 10exp6 to 20 x 10exp6 cell/mL INTRAVEN PLASTIC BAG, INJECTION (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 X 10(6) IU/m2 of recombinant interferon (rIFN)‐alpha‐2A, I.M., twice a week for 6 months
Study: 3437794
Drug: 10 X
Normalized name: PAD,ABDOMINAL 10 X 12 NONSTERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 X 10(6) IU/m2 of recombinant interferon (rIFN)‐alpha‐2A, I.M., twice a week for 6 months
Study: 3437794
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of rIFN
Study: 3437794
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of rIFN
Study: 3437794
Drug: Long-term rIFN‐alpha‐2A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term rIFN‐alpha‐2A therapy
Study: 23524841
Drug: Aspirin (81,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81, 162.5, 325, 650, or 1300 mg daily for 12 weeks)
Study: 19468757
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Risedronate and Estradiol
Study: 9392404
Drug: UNICEF group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: UNICEF group with restrictive fluid supplements and avoidance of bottles and pacifiers during the first 5 days of life
Study: 8156252
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 100 mg i.v. twice a day for 7 days followed by 400 mg orally three times a day
Study: 3784916
Drug: Percutaneous 17
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous 17 beta-oestradiol 3 mg daily + 200 mg oral micronised progesterone
Study: 3784916
Drug: Percutaneous 17
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous 17 beta-oestradiol 3 mg daily + 300 mg oral micronised progesterone
Study: 3784916
Drug: Percutaneous 17
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous 17 beta-oestradiol 3 mg daily + 200 mg or 300 mg oral micronised progesterone